AVBP - CIK 0001868279
The table below shows ArriVent BioPharma, Inc.'s cash flow statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q1 2025 | Q1 2024 | Q1 2023 |
|---|---|---|---|---|
| Operating cash flow | -$41.89M | -$68.01M | -$18.63M | -$16.88M |
| Capital expenditure | - | - | - | - |
| Investing cash flow | $3.58M | $36.82M | - | - |
| Dividends paid | - | - | - | - |
| Stock buybacks | - | - | - | - |
| Financing cash flow | $54.87M | $6.76M |
ArriVent BioPharma, Inc. reported operating cash flow of -$160.59M for fiscal year 2025. That is down 128.7% from -$70.21M in fiscal 2024. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $185.63M |
| $44.97M |